UA75035C2 - Attenuated recombinant herpes virus of cattle of type i (bhv-1), vaccine containing it and a method for the detection of animals injected with recombinant viral vaccine - Google Patents
Attenuated recombinant herpes virus of cattle of type i (bhv-1), vaccine containing it and a method for the detection of animals injected with recombinant viral vaccine Download PDFInfo
- Publication number
- UA75035C2 UA75035C2 UA2001075409A UA2001075409A UA75035C2 UA 75035 C2 UA75035 C2 UA 75035C2 UA 2001075409 A UA2001075409 A UA 2001075409A UA 2001075409 A UA2001075409 A UA 2001075409A UA 75035 C2 UA75035 C2 UA 75035C2
- Authority
- UA
- Ukraine
- Prior art keywords
- virus
- recombinant
- galactosidase
- vaccine
- type
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 36
- 229960005486 vaccine Drugs 0.000 title claims abstract description 18
- 241001465754 Metazoa Species 0.000 title claims abstract description 17
- 241000283690 Bos taurus Species 0.000 title claims abstract description 14
- 241001529453 unidentified herpesvirus Species 0.000 title claims abstract description 12
- 230000002238 attenuated effect Effects 0.000 title claims abstract description 9
- 238000001514 detection method Methods 0.000 title claims abstract description 5
- 229960004854 viral vaccine Drugs 0.000 title 1
- 241000700605 Viruses Species 0.000 claims abstract description 115
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 46
- 239000003550 marker Substances 0.000 claims abstract description 17
- 101000807236 Human cytomegalovirus (strain AD169) Membrane glycoprotein US3 Proteins 0.000 claims abstract description 9
- 230000002068 genetic effect Effects 0.000 claims abstract description 6
- 230000001900 immune effect Effects 0.000 claims abstract description 5
- 241000701024 Human betaherpesvirus 5 Species 0.000 claims abstract description 4
- 230000003053 immunization Effects 0.000 claims abstract description 3
- 108010005774 beta-Galactosidase Proteins 0.000 claims abstract 2
- 108091026890 Coding region Proteins 0.000 claims description 20
- 208000015181 infectious disease Diseases 0.000 claims description 19
- 239000013612 plasmid Substances 0.000 claims description 15
- 230000003472 neutralizing effect Effects 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 230000001744 histochemical effect Effects 0.000 claims description 6
- 238000004458 analytical method Methods 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 5
- 238000003119 immunoblot Methods 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 108700028146 Genetic Enhancer Elements Proteins 0.000 claims description 3
- 230000008488 polyadenylation Effects 0.000 claims description 2
- 230000028996 humoral immune response Effects 0.000 claims 2
- 108010008038 Synthetic Vaccines Proteins 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 238000012151 immunohistochemical method Methods 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 229940124551 recombinant vaccine Drugs 0.000 claims 1
- 238000012217 deletion Methods 0.000 abstract description 35
- 230000037430 deletion Effects 0.000 abstract description 18
- 230000010076 replication Effects 0.000 abstract description 4
- 230000001018 virulence Effects 0.000 abstract description 4
- 102000005936 beta-Galactosidase Human genes 0.000 abstract 1
- 101150072564 gE gene Proteins 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- 244000309466 calf Species 0.000 description 36
- 210000004027 cell Anatomy 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 9
- 238000003780 insertion Methods 0.000 description 9
- 210000003928 nasal cavity Anatomy 0.000 description 9
- 239000012634 fragment Substances 0.000 description 8
- 230000037431 insertion Effects 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 238000009396 hybridization Methods 0.000 description 6
- 241000701083 Bovine alphaherpesvirus 1 Species 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 210000004400 mucous membrane Anatomy 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 206010010741 Conjunctivitis Diseases 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 238000002105 Southern blotting Methods 0.000 description 3
- 108020005202 Viral DNA Proteins 0.000 description 3
- 230000002788 anti-peptide Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 210000003292 kidney cell Anatomy 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 2
- 102000006601 Thymidine Kinase Human genes 0.000 description 2
- 108020004440 Thymidine kinase Proteins 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 244000144980 herd Species 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000002850 nasal mucosa Anatomy 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000007918 pathogenicity Effects 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- -1 9-fluorenylmethoxycarbonyl Chemical group 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 206010048909 Boredom Diseases 0.000 description 1
- 241000710780 Bovine viral diarrhea virus 1 Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 241000237858 Gastropoda Species 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 208000007313 Reproductive Tract Infections Diseases 0.000 description 1
- 206010051497 Rhinotracheitis Diseases 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000012387 aerosolization Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 208000016063 arterial thoracic outlet syndrome Diseases 0.000 description 1
- 208000027697 autoimmune lymphoproliferative syndrome due to CTLA4 haploinsuffiency Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 108060003552 hemocyanin Proteins 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 208000033937 musculocontractural type Ehlers-Danlos syndrome Diseases 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 108010071967 protein K Proteins 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16741—Use of virus, viral particle or viral elements as a vector
- C12N2710/16743—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16761—Methods of inactivation or attenuation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/240,173 US6284251B1 (en) | 1996-02-26 | 1999-01-29 | BHV-1 gene-deleted virus vaccine |
| PCT/US2000/001085 WO2000044884A1 (en) | 1999-01-29 | 2000-01-18 | Bhv-1 gene-deleted virus vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA75035C2 true UA75035C2 (en) | 2006-03-15 |
Family
ID=22905424
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA2001075409A UA75035C2 (en) | 1999-01-29 | 2000-01-18 | Attenuated recombinant herpes virus of cattle of type i (bhv-1), vaccine containing it and a method for the detection of animals injected with recombinant viral vaccine |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US6284251B1 (tr) |
| EP (1) | EP1155119B1 (tr) |
| JP (2) | JP2002535000A (tr) |
| CN (1) | CN1197961C (tr) |
| AT (1) | ATE342731T1 (tr) |
| AU (1) | AU776261B2 (tr) |
| BG (1) | BG105701A (tr) |
| BR (1) | BR0007855A (tr) |
| CA (1) | CA2359177C (tr) |
| CZ (1) | CZ20012589A3 (tr) |
| DE (1) | DE60031374T2 (tr) |
| DK (1) | DK1155119T3 (tr) |
| EA (1) | EA005736B1 (tr) |
| EE (1) | EE200100396A (tr) |
| ES (1) | ES2269101T3 (tr) |
| HK (1) | HK1042512B (tr) |
| HR (1) | HRP20010476B1 (tr) |
| HU (1) | HUP0200560A2 (tr) |
| NO (1) | NO20013697L (tr) |
| NZ (1) | NZ512125A (tr) |
| PT (1) | PT1155119E (tr) |
| SK (1) | SK10702001A3 (tr) |
| TR (1) | TR200102168T2 (tr) |
| UA (1) | UA75035C2 (tr) |
| WO (1) | WO2000044884A1 (tr) |
| YU (1) | YU45601A (tr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2193842B1 (es) * | 2001-06-28 | 2005-06-01 | Consejo Superior De Investigaciones Cientificas | Virus recombinante de la fiebre aftosa que carece del sitio antigenico a y su utilizacion como vacuna marcada. |
| CN101353670B (zh) * | 2007-07-27 | 2012-07-04 | 中国农业科学院哈尔滨兽医研究所 | 牛传染性鼻气管炎病毒重组毒株、其构建方法及应用 |
| US8877211B2 (en) | 2011-06-27 | 2014-11-04 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Bovine herpes virus vaccine with multiple mutations |
| CN104640991B (zh) * | 2012-07-04 | 2017-09-19 | 昆士兰州农渔林业部 | 重组低毒力1型牛疱疹病毒(BoHV‑1)疫苗载体 |
| EP3194968B1 (en) * | 2014-08-01 | 2020-09-02 | The Board of Supervisors of Louisiana State University and Agricultural and Mechanical College | Bovine herpesvirus detection and treatment |
| CN107893056B (zh) * | 2017-12-13 | 2019-08-27 | 江苏省农业科学院 | 山羊疱疹病毒ⅰ型疫苗株及其应用 |
| CN108690835B (zh) * | 2018-05-30 | 2021-08-31 | 内蒙古元山生物科技有限公司 | 一株I型牛疱疹病毒gE缺失毒株及其获取方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8305323D0 (en) | 1983-02-25 | 1983-03-30 | Baylor College Medicine | Infectious bovine rhinotracheitis vaccine |
| US4810634A (en) | 1985-07-29 | 1989-03-07 | The Upjohn Company | Pseudorabies virus mutants incapable of producing glycoprotein X |
| US4703011A (en) | 1985-11-12 | 1987-10-27 | Novagene, Inc. | Thymidine kinase deletion mutants of bovine herpesvirus-1 |
| US5593873A (en) * | 1986-01-27 | 1997-01-14 | Syntro Corporation | Recombinant infectious bovine rhinotracheitis virus |
| WO1989010965A2 (en) | 1988-05-03 | 1989-11-16 | The Upjohn Company | Glycoprotein h of herpes viruses |
| FR2693472B1 (fr) | 1992-06-26 | 1994-12-23 | Rhone Merieux | Mutants du virus de la rhinotrachéite infectieuse bovine, délétés dans l'un des gènes des glycoprotéines mineures, vaccins préparés à partir de ces souches, méthodes de production et méthodes d'utilisation. |
| NL9100989A (nl) | 1991-06-07 | 1993-01-04 | Stichting Centr Diergeneeskund | Bovine herpesvirus type 1 deletiemutanten, daarop gebaseerde vaccins, diagnostische kits voor detectie van bovine herpesvirus type 1. |
| AU672583B2 (en) | 1991-07-18 | 1996-10-10 | Prutech Research And Development Partnership | Recombinant infectious bovine rhinotracheitis virus |
| US5874279A (en) * | 1991-07-18 | 1999-02-23 | Syntro Corporation | Recombinant infectious bovine rhinotracheitis virus |
| CA2057387A1 (en) | 1991-12-11 | 1993-06-12 | Lorne A. Babiuk | Recombinant bovine herpesvirus type 1 polypeptides and vaccines |
| ES2074965B1 (es) * | 1994-01-31 | 1996-05-01 | Hipra Lab Sa | Virus mutante recombinante de rinotraqueitis infecciosa bovina y vacunas que lo contienen. |
-
1999
- 1999-01-29 US US09/240,173 patent/US6284251B1/en not_active Expired - Fee Related
-
2000
- 2000-01-18 CN CNB008031363A patent/CN1197961C/zh not_active Expired - Fee Related
- 2000-01-18 TR TR2001/02168T patent/TR200102168T2/tr unknown
- 2000-01-18 JP JP2000596128A patent/JP2002535000A/ja active Pending
- 2000-01-18 DK DK00904385T patent/DK1155119T3/da active
- 2000-01-18 AU AU26152/00A patent/AU776261B2/en not_active Ceased
- 2000-01-18 EE EEP200100396A patent/EE200100396A/xx unknown
- 2000-01-18 NZ NZ512125A patent/NZ512125A/xx unknown
- 2000-01-18 HU HU0200560A patent/HUP0200560A2/hu unknown
- 2000-01-18 YU YU45601A patent/YU45601A/sh unknown
- 2000-01-18 CA CA002359177A patent/CA2359177C/en not_active Expired - Fee Related
- 2000-01-18 WO PCT/US2000/001085 patent/WO2000044884A1/en active IP Right Grant
- 2000-01-18 PT PT00904385T patent/PT1155119E/pt unknown
- 2000-01-18 UA UA2001075409A patent/UA75035C2/uk unknown
- 2000-01-18 CZ CZ20012589A patent/CZ20012589A3/cs unknown
- 2000-01-18 BR BR0007855-7A patent/BR0007855A/pt not_active IP Right Cessation
- 2000-01-18 EP EP00904385A patent/EP1155119B1/en not_active Expired - Lifetime
- 2000-01-18 AT AT00904385T patent/ATE342731T1/de not_active IP Right Cessation
- 2000-01-18 ES ES00904385T patent/ES2269101T3/es not_active Expired - Lifetime
- 2000-01-18 DE DE60031374T patent/DE60031374T2/de not_active Expired - Fee Related
- 2000-01-18 SK SK1070-2001A patent/SK10702001A3/sk unknown
- 2000-01-18 EA EA200100720A patent/EA005736B1/ru not_active IP Right Cessation
-
2001
- 2001-06-25 HR HR20010476A patent/HRP20010476B1/xx not_active IP Right Cessation
- 2001-07-12 BG BG105701A patent/BG105701A/bg unknown
- 2001-07-27 NO NO20013697A patent/NO20013697L/no not_active Application Discontinuation
-
2002
- 2002-03-25 HK HK02102265.2A patent/HK1042512B/zh not_active IP Right Cessation
-
2006
- 2006-08-23 JP JP2006226616A patent/JP2007020574A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107815441B (zh) | 一种ⅱ型伪狂犬病毒减毒株及其制备方法和应用 | |
| Santos et al. | A novel methodology to develop a foot and mouth disease virus (FMDV) peptide-based vaccine in transgenic plants | |
| JP3247376B2 (ja) | 弱毒化され、遺伝子的に加工されたシュードラビーウイルスｓ−ｐｒｖ−１５５およびその使用 | |
| CN108473539B (zh) | 猫杯状病毒疫苗 | |
| HUT55243A (en) | Process for producing recombinant subunite vaccine against pseudolyssa | |
| KR20150027836A (ko) | 마이코플라스마 히오뉴모니아를 형질전환하기 위한 벡터, 형질전환된 ｍ. 히오뉴모니아 균주, 및 그것의 용도 | |
| US6231863B1 (en) | DNA sequences, molecules, vectors and vaccines for feline calicivirus disease and methods for producing and using same | |
| Phillpotts et al. | Intranasal immunisation with defective adenovirus serotype 5 expressing the Venezuelan equine encephalitis virus E2 glycoprotein protects against airborne challenge with virulent virus | |
| RU2351360C2 (ru) | СПОСОБ ПОЛУЧЕНИЯ ИММУНОГЕННОЙ НЕГЕМОЛИТИЧЕСКОЙ БАКТЕРИИ ВИДА Actinobacillus pleuropneumoniae, БАКТЕРИЯ ВИДА Actinobacillus pleuropneumoniae, ВАКЦИНА ПРОТИВ СВИНОЙ ПЛЕВРОПНЕВМОНИИ (ВАРИАНТЫ), ИММУНОГЕННЫЙ И НЕГЕМОЛИТИЧЕСКИЙ ШТАММ Actinobacillus pleuropneumoniae (ВАРИАНТЫ) | |
| JP3420258B2 (ja) | イヌコロナウイルスサブユニットワクチン | |
| US8017317B2 (en) | gM-negative EHV-mutants | |
| UA75035C2 (en) | Attenuated recombinant herpes virus of cattle of type i (bhv-1), vaccine containing it and a method for the detection of animals injected with recombinant viral vaccine | |
| WO2002000881A1 (en) | Bvdv virus-like particles | |
| JPH05501950A (ja) | 変異株仮性狂犬病ウィルス及びそれを含有するワクチン | |
| KR20230141819A (ko) | 약독화된 아프리카 돼지열병 바이러스 및 백신으로서의 이의 용도 | |
| CN113637648A (zh) | 同时表达pedv变异株s1基因cs区和猪il-18的重组猪伪狂犬病毒株及其应用 | |
| CA2216308A1 (en) | Plasmid vaccine for pseudorabies virus | |
| JP4937460B2 (ja) | ペスチウイルス変異体及びそれを含有するワクチン | |
| WO2024032805A1 (en) | Recombinant porcine coronavirus | |
| JP6101251B2 (ja) | ウイルスベクターにおける抗ｐｒｒｓ組換えワクチン | |
| KR20240083160A (ko) | 돼지 유행성 설사 바이러스 기반 바이러스 벡터 백신 플랫폼 및 이의 용도 |